NATUS MEDICAL INCORPORATED

(NTUS)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
32.65 USD   +1.15%
06/15NATUS MEDICAL INC : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
05/17NATUS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA : Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Natus Medical Incorporated - NTUS
BU
05/06NATUS MEDICAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 1 1371 1156728011 118-
Enterprise Value (EV)1 1 1371 1156728011 1181 118
P/E ratio -49,3x-78,5x-40,9x60,8x33,0x25,1x
Yield ------
Capitalization / Revenue 2,14x2,25x1,62x1,69x2,26x2,16x
EV / Revenue 2,14x2,25x1,62x1,69x2,26x2,16x
EV / EBITDA 16 194 327x16 227 899x----
Price to Book ------
Nbr of stocks (in thousands) 33 41833 79733 52833 77234 243-
Reference price (USD) 34,033,020,023,732,732,7
Announcement Date 02/13/201902/06/202002/25/202102/24/2022--
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 531496416473495517
EBITDA 70,268,7----
Operating profit (EBIT)1 67,960,518,656,965,671,9
Operating Margin 12,8%12,2%4,47%12,0%13,3%13,9%
Pre-Tax Profit (EBT) --19,7-19,4--
Net income1 -22,9-14,1-16,613,234,044,9
Net margin -4,32%-2,85%-4,00%2,78%6,87%8,68%
EPS2 -0,69-0,42-0,490,390,991,30
Dividend per Share ------
Announcement Date 02/13/201902/06/202002/25/202102/24/2022--
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 114129120120124135
EBITDA ------
Operating profit (EBIT)1 13,521,312,814,616,822,0
Operating Margin 11,9%16,6%10,7%12,1%13,6%16,3%
Pre-Tax Profit (EBT) 7,503,63----
Net income1 5,571,751,906,809,3013,9
Net margin 4,89%1,36%1,59%5,65%7,52%10,3%
EPS2 0,160,050,060,200,270,40
Dividend per Share ------
Announcement Date 11/04/202102/24/202205/05/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt ------
Net Cash position ------
Leverage (Debt / EBITDA) ------
Free Cash Flow ------
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share ------
Cash Flow per Share ------
Capex ------
Capex / Sales ------
Announcement Date 02/13/201902/06/202002/25/202102/24/2022--
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 1 118 037 606
Net sales (USD) 473 438 000
Number of employees 1 400
Sales / Employee (USD) 338 170
Free-Float 98,1%
Free-Float capitalization (USD) 1 096 243 961
Avg. Exchange 20 sessions (USD) 12 766 010
Average Daily Capital Traded 1,14%
EPS & Dividend
Year-on-year evolution of the PER